asthma. asthma , unspecified
Conditions
Interventions
Intervention 1: Moderate stage asthmatic subjects whom were not previously treated will be evaluated for clinical findings, spirometry, asthma control test, FENO, sputum cytology, IL-4 ? IFN-? ? IL-17
Treatment - Drugs
Placebo
Moderate stage asthmatic subjects whom were not previously treated will be evaluated for clinical findings, spirometry, asthma control test, FENO, sputum cytology, IL-4 ? IFN-? ? IL-17 and TLR-2 at th
Control group: Moderate stage asthmatic subjects who randomly allocated in control group will be evaluated for clinical findings, spirometry, asthma control test, FENO, sputum cytology, IL-4 ? IFN-? ?
Sponsors
Islamic Azad University of Mashhad
Eligibility
Sex/Gender
All
Age
7 Years to 90 Years
Inclusion criteria
Inclusion criteria: inclusion criteria: New subjects suffering from cough or dyspnea with an intermittent course and history of airway hyper responsiveness; controller drugs was not started; spirometry of the patients showing moderate asthma (forced expiratory volume in the first second between 60 to 80%). Exclusion criteria: mild (FEV1 mare than 80%); severe asthma (FEV1<60%); respiratory infection; treatment with systemic corticosteroid; rhinosinusitis; gastroesophageal reflux disease; other obstructive lung disease; Churg–Strauss syndrome; smokers; vocal cord dysfunction; reactive airway dysfunction syndrome.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fractional exhaled Nitric Oxide (FENO). Timepoint: at the beginning of the study and at the end of the three weeks treatment. Method of measurement: expiratory nitric oxide test with NObreath equipment.;ACT score test. Timepoint: At the beginning of the study and at the end of the three weeks treatment. Method of measurement: ACT questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Interleukin -4 (IL-4). Timepoint: At the begining and at the end of the three weeks of therapy. Method of measurement: ELIZA.;Interleukin-17 (IL-17). Timepoint: At the begining and at the end of the three weeks of therapy. Method of measurement: ELIZA.;Interferon-Y (INF-Y). Timepoint: At the begining and at the end of the three weeks of therapy. Method of measurement: ELIZA.;Toll Like Receptor-2 (TLR-2). Timepoint: At the begining and at the end of the three weeks of therapy. Method of measurement: ELIZA.;Dyspnea. Timepoint: At the beginning of the study and at the end of the three weeks treatment. Method of measurement: MMRC questionnaire.;Forced expiratory volume in one second. Timepoint: at the beginning of the study and at the end of the three weeks treatment. Method of measurement: spirometry.;Inflammatory cells of sputum. Timepoint: At the beginning of the study and at the end of the three weeks treatment. Method of measurement: sputum cytology.;Cough. Timepoint: Before and after three weeks of trial time point. Method of measurement: Clinical assessment. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMajid Mirsadraee
Islamic Azad University- Mashhad Branch
Outcome results
None listed